10435-57-1

Basic information

• Product Name: 5-Cyanosalicylic acid
• Synonyms: 5-Cyanosalicylic acid;5-cyano-2-hydroxybenzoic acid
• CAS NO: 10435-57-1
• Molecular Formula: C₈H₅NO₃
• Molecular Weight: 163.1302
• Mol File: 10435-57-1.mol

Chemical Properties

• Boiling Point: 377.5±37.0 °C(Predicted)
• Appearance: /
• Density: 1.50±0.1 g/cm3(Predicted)
• PKA: 2.35±0.10(Predicted)
• CAS DataBase Reference: 5-Cyanosalicylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Cyanosalicylic acid(10435-57-1)
• EPA Substance Registry System: 5-Cyanosalicylic acid(10435-57-1)

Safety Data

• Hazardous Substances Data: 10435-57-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
5-Cyanosalicylic acid is used as a reagent in the synthesis of organic compounds, serving as a key intermediate in the production of a variety of chemical entities.
Used in Pharmaceutical Production:
As a starting material, 5-Cyanosalicylic acid is utilized in the pharmaceutical industry for the development of new drugs, capitalizing on its anti-inflammatory and antioxidant properties.
Used in Analytical Chemistry:
5-Cyanosalicylic acid is employed as a reagent in analytical chemistry for the detection and quantification of various metal ions in solution, highlighting its role in ensuring the accuracy of chemical analyses.
Used in Research:
5-Cyanosalicylic acid is also used in research settings to explore its potential applications and to further understand its chemical properties and interactions, which can lead to new discoveries and applications in various fields.

Upstream product

• 74901-29-4 5-cyanosalicylaldehyde 
• 767-00-0 4-cyanophenol 
• 150258-60-9 benzyl 5-formyl-2-(benzyloxy)benzoate 
• 773837-37-9 sodium cyanide 
• 89-57-6 5-Aminosalicylic Acid 
• 616-76-2 2-hydroxy-5-formylbenzoic acid 
• 119-30-2 2-hydroxy-5-iodobenzoic acid 
• 84437-12-7 methyl 5-cyanosalicylate 
• 179256-31-6 2-benzyloxy-5-cyanobenzoic acid benzyl ester 
• 544-92-3 copper(I) cyanide 
• 89-55-4 5-bromosalicyclic acid 

Downstream Products

• 518978-03-5 5-cyano-2-[(phenylmethyl)oxy]benzoic acid 
• 179256-31-6 2-benzyloxy-5-cyanobenzoic acid benzyl ester 
• 1426396-67-9 N-(3,5-bis-trifluoromethyl-phenyl)-2-hydroxy-isophthalamide 
• 97005-33-9 5-cyano-salicylamide 
• 84437-04-7 2-Benzoyloxy-5-carbamimidoyl-benzoic acid 
• 84437-06-9 5-Carbamimidoyl-2-hydroxy-benzoic acid 
• 124071-06-3 N-[3-Chloro-4-(4-chloro-phenoxy)-phenyl]-5-cyano-2-hydroxy-benzamide 
• 84437-08-1 2-Hydroxy-5-methoxycarbonimidoyl-benzoic acid; hydrochloride 
• 67127-54-2 5-cyano-2-hydroxy-N-(1⁽²⁾H-tetrazol-5-yl)-benzamide 

Relevant articles and documents

Synthesis, evaluation and docking studies of some 4-thiazolone derivatives as effective lipoxygenase inhibitors

Some promising 4-thiazolone derivatives as lipoxygenase inhibitors were designed, synthesized, characterized and evaluated for anti-inflammatory activity and respective ulcerogenic liabilities. Compounds (1b, 1e, 3b, and 3e) exhibited considerable in vivo

METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY

Disclosed are methods of treating creatine transporter deficiency, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that increases transport of a substrate by a mutant or wild-type creatine transporter. Also disclosed are methods of increasing transport of guanidinoacetic acid or a salt thereof across the blood-brain barrier of a mammal, and methods of decreasing accumulation or the concentration of guanidinoacetic acid or a salt thereof in a mammalian cell.

SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS

Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with a mutation in a protein.

INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS

The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

AMIDINOANILINE DERIVATIVE

Provided are a novel amidine derivative having an activated blood coagulation factor X inhibitory activity, a production method thereof, a production intermediate therefor, and a pharmaceutical composition containing the amidine derivative. An amidinoanil

Benzothiazinone Derivatives and their Use as Antibacterial Agents

The present invention relates to novel benzothiazin derivatives and their use as antibacterial agents in infectious diseases of mammals (humans and animals) caused by bacteria, especially diseases like tuberculosis (TB) and leprosy caused by mycobacteria.

NEW BENZOTHIAZINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS

Novel benzothiazin derivatives of formula (I) and their use as antibacterial agents in infectious diseases caused by bacteria, especially tuberculosis (TB) and leprosy caused by mycobacteria, wherein R1 and R2are, independently each

INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT

A medicament inhibiting the activation of AP-1 which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -X-E wherein each of X and E has the same meaning as that defined above.

IMMUNITY-RELATED PROTEIN KINASE INHIBITORS

[From equivalent EP1510210A1] A medicament having an inhibitory activity against IKK-Aβ and/or MEKK-1 or other protein kinases structurally similar thereto, which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -X-E wherein each of X and E has the same meaning as that defined above.